Biochemistry & Pharmacology: Open Access
Open Access

Lü J

Publications

• Research Article
  Mono-Methyl Selenium and Cancer Therapy: Current Status and Future Translational Research Needs
  Author(s): Barrow K, Jiang C and Lü J Barrow K, Jiang C and Lü J
  
  The human clinical trials with seleno-methionine (SeMet) for prostate cancer prevention and selenized-yeast (contains mostly SeMet) for the prevention of non-small cell lung cancer and prostate cancer in North America conclusively rejected the use of these selenium (Se) forms for cancer prevention in human populations with adequate Se intake. Nevertheless, solid mechanism-based preclinical studies with other Se forms have suggested the potential for their use at pharmacological doses as adjuvant treatment alone and especially as chemo-enhancers for combination cancer therapy. Of the distinct pools of Se metabolites, the mono-methylated Se (MM-Se) has many desirable attributes for cancer therapy, affecting a multitude of crucial molecules and signaling pathways in cancer epithelial cells, vascular endothelial cells and microenvironment. Inorganic selenite/selenide in excess of selenopr.. View More»
  DOI: 10.4172/2167-0501.1000173

  Abstract PDF

Relevant Topics